clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Giacometti A et al. | In vitro activity and killing effect of uperin 3.6 against gram-positive cocci isolated from immunocompromised patients. | 2005 | Antimicrob. Agents Chemother. | pmid:16127075 |
| Peric M et al. | Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates. | 2003 | Antimicrob. Agents Chemother. | pmid:12604536 |
| Watanabe K et al. | Effect of sucralfate on antibiotic therapy for Helicobacter pylori infection in mice. | 2004 | Antimicrob. Agents Chemother. | pmid:15561829 |
| Kim JM et al. | Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea. | 2004 | Antimicrob. Agents Chemother. | pmid:15561865 |
| Jordan MK et al. | Effects of fluconazole and clarithromycin on rifabutin and 25-O-desacetylrifabutin pharmacokinetics. | 2000 | Antimicrob. Agents Chemother. | pmid:10898693 |
| Kato M et al. | Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. | 2000 | Antimicrob. Agents Chemother. | pmid:10898707 |
| Wang G et al. | Multiplex sequence analysis demonstrates the competitive growth advantage of the A-to-G mutants of clarithromycin-resistant Helicobacter pylori. | 1999 | Antimicrob. Agents Chemother. | pmid:10049289 |
| Bakker-Woudenberg IA et al. | Antimycobacterial agents differ with respect to their bacteriostatic versus bactericidal activities in relation to time of exposure, mycobacterial growth phase, and their use in combination. | 2005 | Antimicrob. Agents Chemother. | pmid:15917538 |
| Traunmüller F et al. | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. | 2007 | Antimicrob. Agents Chemother. | pmid:17606673 |
| Kim YC et al. | Effect of CYP3A1(23) induction on clarithromycin pharmacokinetics in rats with diabetes mellitus. | 2005 | Antimicrob. Agents Chemother. | pmid:15917564 |
| Tomioka H et al. | Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. | 1999 | Antimicrob. Agents Chemother. | pmid:10582897 |
| Roblin PM et al. | In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae. | 2010 | Antimicrob. Agents Chemother. | pmid:20038627 |
| Yasuda H et al. | Interaction between biofilms formed by Pseudomonas aeruginosa and clarithromycin. | 1993 | Antimicrob. Agents Chemother. | pmid:8239580 |
| Hammerschlag MR et al. | In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. | 1992 | Antimicrob. Agents Chemother. | pmid:1324650 |
| Nagashima A et al. | Clarithromycin Suppresses Chloride Channel Accessory 1 and Inhibits Interleukin-13-Induced Goblet Cell Hyperplasia in Human Bronchial Epithelial Cells. | 2016 | Antimicrob. Agents Chemother. | pmid:27550358 |
| Rastogi N et al. | Antimycobacterial spectrum of sparfloxacin and its activities alone and in association with other drugs against Mycobacterium avium complex growing extracellularly and intracellularly in murine and human macrophages. | 1991 | Antimicrob. Agents Chemother. | pmid:1667250 |
| Lazard T et al. | Clarithromycin, minocycline, and rifabutin treatments before and after infection of C57BL/6 mice with Mycobacterium avium. | 1993 | Antimicrob. Agents Chemother. | pmid:8215285 |
| Riska PF et al. | Genetic and culture-based approaches for detecting macrolide resistance in Chlamydia pneumoniae. | 2004 | Antimicrob. Agents Chemother. | pmid:15328134 |
| Perronne C et al. | Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages. | 1990 | Antimicrob. Agents Chemother. | pmid:2171421 |
| Goldstein EJ et al. | Activities of telithromycin (HMR 3647, RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antimicrobial agents against unusual anaerobes. | 1999 | Antimicrob. Agents Chemother. | pmid:10543769 |
| Kohno Y et al. | Autobacteriographic studies of clarithromycin and erythromycin in mice. | 1990 | Antimicrob. Agents Chemother. | pmid:2140497 |
| Loreto ES et al. | New insights into the in vitro susceptibility of Pythium insidiosum. | 2014 | Antimicrob. Agents Chemother. | pmid:25223997 |
| Sassa K et al. | Differential modulatory effects of clarithromycin on the production of cytokines by a tumor. | 1999 | Antimicrob. Agents Chemother. | pmid:10543765 |
| Clark C et al. | In vitro selection of resistance in Haemophilus influenzae by amoxicillin-clavulanate, cefpodoxime, cefprozil, azithromycin, and clarithromycin. | 2002 | Antimicrob. Agents Chemother. | pmid:12183253 |
| Osborne CS et al. | In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models. | 2009 | Antimicrob. Agents Chemother. | pmid:19596876 |
| Tateda K et al. | Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin. | 1996 | Antimicrob. Agents Chemother. | pmid:8891128 |
| Hardy DJ et al. | Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. | 1990 | Antimicrob. Agents Chemother. | pmid:2143642 |
| Hunt Gerardo S et al. | Comparison of Etest to broth microdilution method for testing Streptococcus pneumoniae susceptibility to levofloxacin and three macrolides. | 1996 | Antimicrob. Agents Chemother. | pmid:8891154 |
| Lemaire S et al. | Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. | 2009 | Antimicrob. Agents Chemother. | pmid:19564365 |
| Steele-Moore L et al. | In vitro activities of clarithromycin and azithromycin against clinical isolates of Mycobacterium avium-M. intracellulare. | 1999 | Antimicrob. Agents Chemother. | pmid:10383373 |
| Fernandes PB et al. | In vitro and in vivo activities of clarithromycin against Mycobacterium avium. | 1989 | Antimicrob. Agents Chemother. | pmid:2530933 |
| Leuthner KD et al. | Pulsatile delivery of clarithromycin alone or in combination with amoxicillin against Streptococcus pneumoniae. | 2006 | Antimicrob. Agents Chemother. | pmid:16436754 |
| GarcÃa-Arata MI et al. | Mutations in 23S rRNA in Helicobacter pylori conferring resistance to erythromycin do not always confer resistance to clarithromycin. | 1999 | Antimicrob. Agents Chemother. | pmid:9925537 |
| Hoffner SE et al. | Susceptibility of Mycobacterium malmoense to antibacterial drugs and drug combinations. | 1993 | Antimicrob. Agents Chemother. | pmid:8392308 |
| Zhou Z et al. | Macrolide-resistant Mycoplasma pneumoniae in adults in Zhejiang, China. | 2015 | Antimicrob. Agents Chemother. | pmid:25451048 |
| Kuo CC et al. | In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae. | 1996 | Antimicrob. Agents Chemother. | pmid:8913488 |
| Hogan PA and Sheehan DJ | Macrolide susceptibility and beta-lactamase production among haemophilus influenzae isolates in the United States, 1996-1997. | 1998 | Antimicrob. Agents Chemother. | pmid:9835536 |
| Diacon AH et al. | Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. | 2012 | Antimicrob. Agents Chemother. | pmid:22391540 |
| Cirioni O et al. | Efficacy of the combination of tachyplesin III and clarithromycin in rat models of Escherichia coli sepsis. | 2008 | Antimicrob. Agents Chemother. | pmid:18779356 |
| Mor N and Heifets L | MICs and MBCs of clarithromycin against Mycobacterium avium within human macrophages. | 1993 | Antimicrob. Agents Chemother. | pmid:8431006 |
| Abduljalil K et al. | Modeling the autoinhibition of clarithromycin metabolism during repeated oral administration. | 2009 | Antimicrob. Agents Chemother. | pmid:19414584 |
| Rouse MS et al. | Efficacy of azithromycin or clarithromycin for prophylaxis of viridans group streptococcus experimental endocarditis. | 1997 | Antimicrob. Agents Chemother. | pmid:9257739 |
| Cynamon MH et al. | Activity of ABT-773 against Mycobacterium avium complex in the beige mouse model. | 2000 | Antimicrob. Agents Chemother. | pmid:10991883 |
| Fong IW et al. | Influence of clarithromycin on early atherosclerotic lesions after Chlamydia pneumoniae infection in a rabbit model. | 2002 | Antimicrob. Agents Chemother. | pmid:12121899 |
| Pryjma M et al. | Antagonism between Front-Line Antibiotics Clarithromycin and Amikacin in the Treatment of Mycobacterium abscessus Infections Is Mediated by the Gene. | 2017 | Antimicrob. Agents Chemother. | pmid:28874379 |
| Bolhuis MS et al. | Clinical validation of the analysis of linezolid and clarithromycin in oral fluid of patients with multidrug-resistant tuberculosis. | 2013 | Antimicrob. Agents Chemother. | pmid:23689722 |
| Spaniol V et al. | Moraxella catarrhalis AcrAB-OprM efflux pump contributes to antimicrobial resistance and is enhanced during cold shock response. | 2015 | Antimicrob. Agents Chemother. | pmid:25583725 |
| Horgen L et al. | Pulsed-exposure and postantibiotic leukocyte enhancement effects of amikacin, clarithromycin, clofazimine, and rifampin against intracellular Mycobacterium avium. | 1998 | Antimicrob. Agents Chemother. | pmid:9797242 |
| Phillips RO et al. | Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease. | 2014 | Antimicrob. Agents Chemother. | pmid:24323473 |
| Conte JE et al. | Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin. | 1995 | Antimicrob. Agents Chemother. | pmid:7726492 |
| Ménard A et al. | PCR-restriction fragment length polymorphism can also detect point mutation A2142C in the 23S rRNA gene, associated with Helicobacter pylori resistance to clarithromycin. | 2002 | Antimicrob. Agents Chemother. | pmid:11897613 |
| Matic V et al. | Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin. | 2004 | Antimicrob. Agents Chemother. | pmid:15504828 |
| Nagai K et al. | Activities of a new fluoroketolide, HMR 3787, and its (des)-fluor derivative RU 64399 compared to those of telithromycin, erythromycin A, azithromycin, clarithromycin, and clindamycin against macrolide-susceptible or -resistant Streptococcus pneumoniae and S. pyogenes. | 2001 | Antimicrob. Agents Chemother. | pmid:11600391 |
| Visalli MA et al. | Susceptibility of penicillin-susceptible and -resistant pneumococci to dirithromycin compared with susceptibilities to erythromycin, azithromycin, clarithromycin, roxithromycin, and clindamycin. | 1997 | Antimicrob. Agents Chemother. | pmid:9303375 |
| Spyridaki A et al. | Effect of clarithromycin in inflammatory markers of patients with ventilator-associated pneumonia and sepsis caused by Gram-negative bacteria: results from a randomized clinical study. | 2012 | Antimicrob. Agents Chemother. | pmid:22564837 |
| Ednie LM et al. | Comparative antianaerobic activities of the ketolides HMR 3647 (RU 66647) and HMR 3004 (RU 64004). | 1997 | Antimicrob. Agents Chemother. | pmid:9303406 |
| Seyama S et al. | Clarithromycin Resistance Mechanisms of Epidemic β-Lactamase-Nonproducing Ampicillin-Resistant Haemophilus influenzae Strains in Japan. | 2016 | Antimicrob. Agents Chemother. | pmid:26953210 |
| Berry V et al. | Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae. | 1998 | Antimicrob. Agents Chemother. | pmid:9835514 |
| Furuie H et al. | Intrapulmonary pharmacokinetics of S-013420, a novel bicyclolide antibacterial, in healthy Japanese subjects. | 2010 | Antimicrob. Agents Chemother. | pmid:19933801 |
| Chu SY et al. | Absolute bioavailability of clarithromycin after oral administration in humans. | 1992 | Antimicrob. Agents Chemother. | pmid:1387301 |
| Yajko DM et al. | Comparison of the intracellular activities of clarithromycin and erythromycin against Mycobacterium avium complex strains in J774 cells and in alveolar macrophages from human immunodeficiency virus type 1-infected individuals. | 1992 | Antimicrob. Agents Chemother. | pmid:1387302 |
| de Lalla F et al. | Clarithromycin-ciprofloxacin-amikacin for therapy of Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS. | 1992 | Antimicrob. Agents Chemother. | pmid:1387303 |
| Zhanel GG et al. | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. | 2008 | Antimicrob. Agents Chemother. | pmid:18285482 |
| Luna-Herrera J et al. | Antituberculosis activity of clarithromycin. | 1995 | Antimicrob. Agents Chemother. | pmid:8593004 |
| Ellis LC et al. | Postantibiotic effect of clarithromycin alone and combined with ethambutol against Mycobacterium avium complex. | 1995 | Antimicrob. Agents Chemother. | pmid:8593025 |
| Truffot-Pernot C et al. | Clarithromycin is inactive against Mycobacterium tuberculosis. | 1995 | Antimicrob. Agents Chemother. | pmid:8593032 |
| Ramón-GarcÃa S et al. | Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen. | 2011 | Antimicrob. Agents Chemother. | pmid:21576426 |
| Naik S and Ruck R | In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex. | 1989 | Antimicrob. Agents Chemother. | pmid:2817858 |
| Cohen Y et al. | Activities of WIN-57273, minocycline, clarithromycin, and 14-hydroxy-clarithromycin against Mycobacterium avium complex in human macrophages. | 1992 | Antimicrob. Agents Chemother. | pmid:1332586 |
| Collins LA et al. | Green fluorescent protein reporter microplate assay for high-throughput screening of compounds against Mycobacterium tuberculosis. | 1998 | Antimicrob. Agents Chemother. | pmid:9527783 |
| Phillips RO et al. | Reply to "compliance with antimicrobial therapy for buruli ulcer". | 2014 | Antimicrob. Agents Chemother. | pmid:25225343 |
| Klis S et al. | Compliance with antimicrobial therapy for buruli ulcer. | 2014 | Antimicrob. Agents Chemother. | pmid:25225342 |
| Mukherjee D et al. | Vancomycin and Clarithromycin Show Synergy against . | 2017 | Antimicrob. Agents Chemother. | pmid:28923867 |
| Tsay FW et al. | A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance. | 2017 | Antimicrob. Agents Chemother. | pmid:28807915 |
| Klemens SP et al. | Activity of clarithromycin against Mycobacterium avium complex infection in beige mice. | 1992 | Antimicrob. Agents Chemother. | pmid:1336945 |
| Bermudez LE et al. | Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy. | 1998 | Antimicrob. Agents Chemother. | pmid:9449283 |
| Portaels F et al. | In vitro susceptibility of Mycobacterium ulcerans to clarithromycin. | 1998 | Antimicrob. Agents Chemother. | pmid:9687409 |
| Andini N and Nash KA | Intrinsic macrolide resistance of the Mycobacterium tuberculosis complex is inducible. | 2006 | Antimicrob. Agents Chemother. | pmid:16801446 |
| Hsu PI et al. | Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection. | 2014 | Antimicrob. Agents Chemother. | pmid:25070099 |
| Secka O et al. | Antimicrobial susceptibility and resistance patterns among Helicobacter pylori strains from The Gambia, West Africa. | 2013 | Antimicrob. Agents Chemother. | pmid:23263004 |
| Rana KZ et al. | Clarithromycin does not affect phosphorylation of zidovudine in vitro. | 1996 | Antimicrob. Agents Chemother. | pmid:8843311 |
| Finch R et al. | Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. | 2002 | Antimicrob. Agents Chemother. | pmid:12019085 |
| Prazeres Magalhães P et al. | Helicobacter pylori primary resistance to metronidazole and clarithromycin in Brazil. | 2002 | Antimicrob. Agents Chemother. | pmid:12019131 |
| Mougari F et al. | Selection of Resistance to Clarithromycin in Mycobacterium abscessus Subspecies. | 2017 | Antimicrob. Agents Chemother. | pmid:27799212 |
| Yamaguchi H et al. | Chlamydia pneumoniae resists antibiotics in lymphocytes. | 2003 | Antimicrob. Agents Chemother. | pmid:12760877 |
| Kutlin A et al. | Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection Model. | 2002 | Antimicrob. Agents Chemother. | pmid:11796350 |
| Nash KA | Effect of drug concentration on emergence of macrolide resistance in Mycobacterium avium. | 2001 | Antimicrob. Agents Chemother. | pmid:11353601 |
| Jacks SS et al. | In vitro susceptibilities of Rhodococcus equi and other common equine pathogens to azithromycin, clarithromycin, and 20 other antimicrobials. | 2003 | Antimicrob. Agents Chemother. | pmid:12709351 |
| Giamarellos-Bourboulis EJ et al. | Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa. | 2004 | Antimicrob. Agents Chemother. | pmid:14693524 |
| Hultén K et al. | Macrolide resistance in Helicobacter pylori: mechanism and stability in strains from clarithromycin-treated patients. | 1997 | Antimicrob. Agents Chemother. | pmid:9371366 |
| Alffenaar JW et al. | Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection. | 2010 | Antimicrob. Agents Chemother. | pmid:20585115 |
| Kishii K et al. | In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae. | 2010 | Antimicrob. Agents Chemother. | pmid:20585130 |
| Hoffman HL et al. | Influence of macrolide susceptibility on efficacies of clarithromycin and azithromycin against Streptococcus pneumoniae in a murine lung infection model. | 2003 | Antimicrob. Agents Chemother. | pmid:12543686 |
| Polis MA et al. | Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infection. | 1997 | Antimicrob. Agents Chemother. | pmid:9257746 |
| Walker KJ et al. | Evaluation of antimicrobial activities of clarithromycin and 14-hydroxyclarithromycin against three strains of Haemophilus influenzae by using an in vitro pharmacodynamic model. | 1994 | Antimicrob. Agents Chemother. | pmid:7811010 |
| Liu KY et al. | Efficacy and pharmacological mechanism of pronase-enhanced low-dose antibiotics for Helicobacter pylori eradication. | 2014 | Antimicrob. Agents Chemother. | pmid:24687504 |
| Chen D et al. | Phenotypic and Molecular Antimicrobial Susceptibility of Helicobacter pylori. | 2017 | Antimicrob. Agents Chemother. | pmid:28167563 |
| Obregón-Henao A et al. | Susceptibility of Mycobacterium abscessus to antimycobacterial drugs in preclinical models. | 2015 | Antimicrob. Agents Chemother. | pmid:26303795 |
| Piccolomini R et al. | Bacteriostatic and bactericidal in vitro activities of clarithromycin and erythromycin against periodontopathic Actinobacillus actinomycetemcomitans. | 1998 | Antimicrob. Agents Chemother. | pmid:9797240 |
| Patel KB et al. | Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. | 1996 | Antimicrob. Agents Chemother. | pmid:8891147 |